Donor cell leukemia (DCL) is a rare complication of allogeneic hematopoietic SCT (allo-HSCT). Chimerism analysis is usually used to distinguish DCL from relapse of original leukemia. In cases of sex-mismatched donors, sex-chromosome analysis is widely used to assess the chimeric status. We report a case of Philadelphia (Ph) chromosome-positive ALL (Ph þ ALL). Sex-chromosome analyses showed a donor pattern at relapse, leading to a misleading diagnosis of DCL.
A 44-year-old Japanese male developed Ph þ ALL and achieved CR after chemotherapy including dasatinib. He then received allogeneic PBSCT from a sex-mismatched and HLA-identical sibling donor, using a conditioning regimen consisting of etoposide, CY and TBI. Prophylaxis for GVHD included CYA plus MTX. The patient developed chronic hepatic GVHD 4 months after PBSCT and was given prednisolone (PSL) and mycophenolate mofetil (MMF). Complete donor-type chimerism was maintained. FISH revealed XX in 100% of BM, whereas G-band karyotyping analysis showed the donor-type chromosome. No leukemic cells were observed in BM 15 months after PBSCT, although minor BCR-ABL mRNA was detected. Based on the recognition of molecular relapse, the patient was started on dasatinib, and PSL and MMF were stopped. T315I BCR-ABL mutation was confirmed after starting dasatinib. The number of leukemic cells gradually increased in peripheral blood and BM. FISH revealed that 99.8% of the leukemic cells were XX, whereas G-band karyotyping showed complexed chromosomes, including XX. DCL was therefore suspected. However, flow-cytometric analysis (FCM) revealed the same pattern as observed at original diagnosis of ALL, and T315I BCR-ABL mutation was demonstrated. These analyses were inconsistent with those of DCL. We could not assess the patient's G-band karyotyping, which showed complexed karyotypes including chromosome 9, whereas original karyotypes had shown a donor pattern of inv(9)(p12q13). 46,XX,inv(9)(p12q13) is the normal variant observed in 1.65% of the Japanese population. Table 1 shows the results of analyses corresponding to the clinical history ( Supplementary Figures 1 and 2 ).
Taken together, the results of sex-chimerism analysis indicated that the patient's leukemic cells were of donor origin. However, Ph-chromosome analysis, FCM, T315I BCR-ABL mutation and VNTR analyses indicated that the cells were of recipient origin. Although HLA typing is one of the most important methods for analyzing chimerism, we could not use it because the donor was fully HLAmatched. We interpreted DCL based on sex-chromosome analyses, whereas other cases showed ALL relapse. As recently reported, DCL incidence after transplants is approximately 5%. 2 However, large surveys reported an estimated DCL incidence of approximately 0.1-0.5% after transplant, whereas DCL after umbilical cord blood transplantation has a higher incidence. 3 Little is known about the precise mechanisms contributing to DCL. The T315I BCR-ABL mutation was repeatedly demonstrated after transplantation in this case. Pfeifer et al. 4 reported that a kinasedomain mutation was detected in 40% of newly diagnosed and imatinib-naive Ph chromosome-positive ALL patients by denaturing high-performance liquid chromatography, cDNA sequencing and allele-specific PCR. Pre-existing levels of the (1)t(1;20),der(4)t(4;22)(q33B34;q12B13)(q33),der(6)t(6;9)(q23;q34),del(7)(p15),der(7)t(7;18)(p22;q21), À 9, der(9)(9pter-9q34::22q11.2-22q13::6q23-6qter),der(11)t(1;11)(p31;q23),del(13)(q14q22),der(15)t(15;20)(q22;q11.2),del(16)(q22),del(18)(q12), À 20, der(22)t(9;22)(q34;q11.2). Complex(2):45,X, þ X, À Y,t(1;2)(p32;p15), þ der(1)t(1;20)(p32;q11.2), þ der(1)t(1;20),add(2)(p13),der(4)t(4;22)(q33B34;q12B13)(q33), der(6)t(6;9)(q23;q34),del(7)(p15),der(7)t(7;18)(p22;q21), À 9,der(9)(9pter-9q34::22q11.2-22q13::6q23-6qter),der(11)t(1;11)(p31;q23),del(13)(q14q22),der(15) t(15;20)(q22;q11.2),del(16)(q22),del(18)(q12), À 20,der(22)t(9;22)(q34;q11.2). NOTES: Donor's karyotype analysis was 46,XX,inv(9)(p12q13).
mutation were below the detection sensitivity of reverse transcription PCR. T315I BCR-ABL mutations in our case may also have existed below detectable limits at onset in our case. However, it cannot be assumed that this mutation would not have been observed if the leukemic cells had been derived from the donor. Furthermore, VNTR analysis revealed the recipient pattern and is considered to be the most sensitive technique for discriminating between individuals, as previously reported. 5 These findings suggested leukemic cells of recipient origin. It is therefore significant to consider all these analyses when investigating ALL relapse. Sex-chromosome analyses, which indicated leukemic cells of donor origin, indicated that the Y chromosome was lost and the X chromosome duplicated. Additional X chromosomes are observed in approximately 4% of ALL patients and are not considered to be a prognostic factor. 6 Whereas, Y-chromosome loss is occasionally observed in hematological disorders and is reportedly a prognostic factor in AML and myelodysplastic syndrome but not in ALL. However, the incidence of Y-chromosome loss in ALL patients is unknown. Y-chromosome loss reported in some malignancies has no role in the etiology of malignant cell transformation, but provides an accelerated process of Y decay associated with cancer. 7 The reason for Y-chromosome loss and the additional X chromosome not being involved in the relapse in our case was not determined. The karyotypes of patients with acute leukemia at relapse or disease progression after allo-HSCT are different in 68% of cases regardless of whether they had a karyotype change or had no significant difference in OS and survival after relapse. 8 Two cases reported in the literature showed changes in sex chromosomes similar to those observed in the present case. 9, 10 One was detected when newly diagnosed 9 and the other after sex-mismatched allo-HSCT. 10 In the latter case, sex-chromosome analysis showed leukemic cells seemingly of donor origin, although relapse was confirmed by the recipient cells showing short tandem repeats identical to those of the donor cells. To our knowledge, this is the first report of a similar case in an adult. Several methods can be used to evaluate the chimeric state after sex-mismatched HSCT. The rare case described here suggests that it is important to acquire more results from these analyses when evaluating the chimeric state. Supplementary Information is available at the website of Bone Marrow Transplantation.
